For the Inventor, By the Inventor

Enter assignee name

Seattle, WA, United States of America

Cell Therapeutics, Inc.

USPTO Granted Patents = 103

% Expired Patents = 20.4

EPO Patents = 4

Trademarks = 5

Forward Citations = 1,047

Loading Chart...

Loading Chart...

75 inventors (with patents filed for the assignee):

J Peter Klein (50 out of 50 patents)

Gail E Underiner (33 out of 33 patents)

Anil M Kumar (28 out of 37 patents)

4. Jack W Singer (25 out of 28 patents)

5. David J Porubek (21 out of 25 patents)

6. David W Leung (20 out of 28 patents)

7. Paul Woodson (18 out of 18 patents)

8. Alistair J Leigh (15 out of 15 patents)

9. Glenn C Rice (12 out of 14 patents)

10. James A Bianco (12 out of 15 patents)

11. Baoqing Gong (10 out of 10 patents)

12. John Michnick (9 out of 9 patents)

13. John E Tulinsky (9 out of 11 patents)

14. Stuart L Bursten (8 out of 10 patents)

15. David M Hollenback (7 out of 7 patents)

Core Competencies:

Neurotrophic Agents

Tumor Necrosis Factor Inhibitors

Polyglutamic Acid

Biologically Active Polypeptides

Prostaglandins

Xanthine Compounds

Angiogenic Lipids

LPAAT-β Inhibitors

Therapeutic Compounds

Ocular Hypertension

Tricyclic Compounds

Cell Proliferation

103 patents: Sort by Forward Citations

1. 12128104 - Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (FAS) or FAS ligand (FASL) inhibitor, a tumor necrosis factor-alpha (TNF-alpha) or TNF receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease inhibitor (2024-10-29),

2. 11147855 - Methods for treating glaucoma or ocular hypertension comprising delivery of prostaglandins to the vitreous humour (2021-10-19),

3. 8748577 - Conjugates of biologically active polypeptides having an increased in vivo half-life (2014-06-10),

4. 8426625 - Bis-platinum complexes with antitumor activity (2013-04-23),

5. 8415338 - Oxygen linked pyrimidine derivatives (2013-04-09),

6. 8329853 - Process for the preparation of poly-α-glutamic acid and derivatives thereof (2012-12-11),

7. 8318503 - Method for determining the amount of conjugated taxane in polyglut acid-taxane conjugates (2012-11-27),

8. 8129348 - Conjugates of biologically active proteins having a modified in vivo half-life (2012-03-06),

9. 7618968 - Aryl triazines as LPAAT-β inhibitors and uses thereof (2009-11-17),

10. 7608620 - LPAAT-β inhibitors and uses thereof (2009-10-27),

11. 7419984 - Pyrimidines and uses thereof (2008-09-02),

12. 7399860 - Manufacture of polyglutamate-therapeutic agent conjugates (2008-07-15),

13. 7291616 - Aryl triazines as LPAAT-β inhibitors and uses thereof (2007-11-06),

14. 7247630 - Uses of tricyclic compounds (2007-07-24),

15. 7208507 - Pyridines and uses thereof (2007-04-24),

Cell Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative cancer treatments. They aim to provide novel therapies that improve the lives of patients with difficult-to-treat cancers. With a strong pipeline of potential drug candidates, Cell Therapeutics is committed to conducting rigorous clinical trials and obtaining regulatory approvals. Visit their website for more information.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

103 Patents

#20 in Seattle, WA

#63 in Washington

#3,684 in US

#7,571 in the World

Seattle, WA, United States of America

Cell Therapeutics, Inc.

Forward Citations = 1,047

75 inventors:

J Peter Klein (50 out of 50 patents)

Gail E Underiner (33 out of 33 patents)

Anil M Kumar (28 out of 37 patents)

4. Jack W Singer (25 out of 28 patents)

5. David J Porubek (21 out of 25 patents)

Please report any incorrect information to [email protected]

Loading…